



Supplementary Figure 4. Ratio surface expression by flow cytometry (lenalidomide: vehicle treatment) for percent CAR in CD4+ and CD8+ T cells, percent CD27-/CCR7- in CAR+ CD4+ and CAR+ CD8+, and percent CD45RA- in CAR+ CD4+ and CAR+ CD8+ following 7 days of BCMA bead stimulation in the presence of lenalidomide compared to vehicle.